Detail of "175033-36-0"

Reference

Nitric oxide-releasing aspirin inhibits vasoconstriction in perfused tail artery of normotensive and spontaneously hypertensive rats

Nitric oxide-releasing aspirin inhibits vasoconstriction in perfused tail artery of normotensive and spontaneously hypertensive rats. Rossoni, Giuseppe; Manfredi, Barbara; Del Soldato, Piero; Polvani, Gianluca; Berti, Ferruccio (Department of Pharmacological Sciences, University of Milan, Milan, Italy). European Journal of Pharmacology, 477(1), 59-68 (English) 2003 Elsevier Science B.V. CODEN: EJPHAZ. ISSN: 0014-2999. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) The aim of this study was to investigate the capacity of the 2-(acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester (NCX 4016), a nitric oxide (NO)-releaser deriv.In this article, certain chemicals are used. Some of their cas registry numbers are 7665-99-8 and 175033-36-0 of aspirin, to decrease blood pressure in spontaneously hypertensive rats (SHR) and to counteract the adrenergic vasoconstriction in perfused tail artery of these animals. Oral treatment for 10 consecutive days with NCX 4016 (100 mmol/kg) in SHR and their genetic controls Wistar Kyoto (WKY) rats resulted in a redn. of blood pressure in SHR but not in WKY rats. In SHR, the NCX 4016 treatment increased the serum nitrite/nitrate and diminished the serum thromboxane B2, whereas aspirin did not change blood pressure but abolished the serum thromboxane B2. Perfused tail arteries excised from vehicle-treated SHR exhibited a significant impairment of endothelium-dependent vasorelaxant function. These vessels, prepd. from SHR or WKY rats treated orally with NCX 4016 (10, 30 and 100 mmol/kg for 7 consecutive days), revealed a dose-dependent decrease in vasoconstriction in response to transmural nerve stimulation and norepinephrine, whereas aspirin was ineffective. Furthermore, in tail arteries of both SHR and WKY rats treated orally with NCX 4016 (100 mmol/kg for 7 consecutive days), the cGMP increased significantly. In conclusion, NCX 4016, by releasing NO and increasing cGMP in vascular tissue, reduces sympathetic-mediated vasoconstriction in resistance vessels and lowers blood pressure in SHR. .

Chronicles in drug discovery

All Rights Reserved. Chronicles in drug discovery. Moral, M. A.; Khurdayan, V. K.Some commonly used reagents like 175033-36-0 and 9028-35-7 are used in this experiment.; Bozzo, J. (Spain). Drug News & Perspectives, 19(8), 485-489 (English) 2006 Prous Science. CODEN: DNPEED. ISSN: 0214-0934. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A review. Chronicles in Drug Discovery features special interest reports on advances in drug discovery and development. This month we focus on the progress of the ongoing search for safe and effective chemopreventive agents. Chemoprevention is a strategy to decrease the risk of developing cancer by using agents that prevent or abrogate carcinogenic processes. Bowman-Birk inhibitor conc., budesonide, NCX-4016 and statins are all undergoing investigation in the clin. setting as potential chemopreventive agents for head and neck, lung, colon and breast cancers, resp. .